Clinical Trial Update: Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of thalidomide and Doxil in patients with androgen-independent prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Thalomid (thalidomide)

Snippet

Sponsor: University of Pittsburgh | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-12